EMA PRAC Recommends Valproate Product Information Update After Inconclusive NDD Evidence Review

Regulatory affairs teams holding marketing authorisations for valproate-containing products in the EU face immediate labelling obligations after EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded its June 2026 review with a split verdict: evidence linking paternal valproate exposure to neurodevelopmental disorders (NDDs) in offspring is inconsistent, yet precautionary measures introduced in 2024 will remain in force pending a larger confirmatory study.

The committee's position reflects the weight of the available evidence. Most retrospective observational studies reviewed did not find an increased risk of NDDs in children born to men treated with valproate in the three months before conception. One study did suggest a possible association, and methodological differences across the study pool, including patient selection criteria and adjustment for underlying conditions, preclude a definitive causal determination. PRAC concluded it cannot distinguish whether any observed signal is attributable to valproate or to the fathers' underlying medical conditions such as epilepsy or bipolar disorder.

The 2024 precautionary measures, introduced following a post-authorisation safety study (PASS) drawing on Danish, Norwegian, and Swedish registry data, stay in place. At that time, PRAC acknowledged the PASS data carried limitations and requested marketing authorisation holders to commission a larger, purpose-designed study. That study is currently ongoing and is expected to conclude in 2028; its results will determine whether further label change obligations follow.

For QA directors and regulatory leads, the near-term action is concrete: PRAC has recommended updating the medicines' product information, the healthcare professional guide, and the patient guide for male patients to reflect the most current data on NDDs. Valproate medicines are authorised across EU Member States for epilepsy and bipolar disorder, and in some Member States for migraine prevention, meaning the labelling update obligation spans a broad product portfolio. The full assessment report will be published on the EMA website in due course.

The signal itself was triggered in July 2025 following publication of a Danish nationwide registry-based study that did not suggest an increased NDD risk, prompting PRAC to reassess the totality of evidence before reaching its current position.

Marketing authorisation holders should map their submission timelines against the 2028 study conclusion date, as PRAC's language on remaining uncertainties signals that the label is unlikely to be considered stable until those results are assessed.

Source: European Medicines Agency (EMA) via ema.europa.eu, 12 June 2026.